OC57 - A multinational observational study on the clinical characteristics and treatments offered to women with polycystic ovary syndrome (PCOS)-related skin conditions presenting to specialist clinics
Abstract
Although guidelines exist for managing skin conditions within the general population, there is paucity of data on how these are managed in women with polycystic ovary syndrome (PCOS) in real world setting. This study aimed to describe the clinical characteristics of women with PCOS presenting to specialist clinics, and to understand the trends in treatments offered to women with PCOS-related skin concerns.
A multi-centre retrospective observational study was conducted across the UK, Turkey, Greece, Georgia, and India. Patients referred to a PCOS clinic between January 2020 and December 2023 were included. Data, including details of the PCOS- related skin conditions and treatments offered after the specialist clinic consultation, was recorded on standardised Google Forms. The Chi-square test and Wilcoxon-rank- sum test were used to analyse categorical and continuous variables respectively using SPSS v30.0.
A total of 1313 participants with a diagnosis of PCOS were included, of which 1041 participants had PCOS-related skin concerns. The median age of the participants was 27.0 (IQR 24.0-31.0) years. Most participants were White (52.7%), followed by Asian (33.1%). Hirsutism was the most common skin manifestation across all five countries, affecting 90.1% of the cohort. Metformin and progesterone-only pill (POP) were the most prescribed first and second treatment options respectively. However, treatment options differed between countries; metformin was the most prescribed first…
How strong is the evidence?
Evidence Hub reads this as a cohort study, done in people. Its evidence level is 3 of 5 (Moderate · trial / cohort / secondary analysis). Trials without a large randomized design, cohorts and secondary analyses give moderate evidence. Reported size: 1,313 participants or records.
Read the paper
Related studies
- Increased expression of circulating miRNA-93 in women with polycystic ovary syndrome may represent a novel, non-invasive biomarker for diagnosis
- Identification of key genes associated with polycystic ovary syndrome (PCOS) and ovarian cancer using an integrated bioinformatics analysis
- Identification of key pathways and genes in polycystic ovary syndrome via integrated bioinformatics analysis and prediction of small therapeutic molecules
- Regulation of Androgen Receptor Expression Alters AMPK Phosphorylation in the Endometrium: In Vivo and In Vitro Studies in Women with Polycystic Ovary Syndrome
- Effect of oral administration of low-dose follicle stimulating hormone on hyperandrogenized mice as a model of polycystic ovary syndrome
- Systems pharmacology to investigate the interaction of berberine and other drugs in treating polycystic ovary syndrome
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.